Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI; HEP-COVID Investigators. Spyropoulos AC, et al. JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203. JAMA Intern Med. 2021. PMID: 34617959 Free PMC article. Clinical Trial.
Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model.
Goldenberg NA, Spyropoulos AC, Halperin JL, Kessler CM, Schulman S, Turpie AG, Skene AM, Cutler NR, Hiatt WR; Antithrombotic Trials Leadership and Steering Group. Goldenberg NA, et al. Among authors: spyropoulos ac. Blood. 2011 Feb 17;117(7):2089-92. doi: 10.1182/blood-2010-09-308858. Epub 2010 Nov 10. Blood. 2011. PMID: 21068436 Free PMC article.
Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach.
Kittelson JM, Spyropoulos AC, Halperin JL, Kessler CM, Schulman S, Steg G, Turpie AG, Cutler NR, Hiatt WR, Goldenberg NA; Antithrombotic Trials Leadership and Steering (ATLAS) Group. Kittelson JM, et al. Among authors: spyropoulos ac. J Thromb Haemost. 2013 Aug;11(8):1443-8. doi: 10.1111/jth.12324. J Thromb Haemost. 2013. PMID: 23773172 Free PMC article. Review.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.
Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad V, Ortel TL; BRIDGE Investigators. Douketis JD, et al. Among authors: spyropoulos ac. N Engl J Med. 2015 Aug 27;373(9):823-33. doi: 10.1056/NEJMoa1501035. Epub 2015 Jun 22. N Engl J Med. 2015. PMID: 26095867 Free PMC article. Clinical Trial.
Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings.
Goldenberg NA, Abshire T, Blatchford PJ, Fenton LZ, Halperin JL, Hiatt WR, Kessler CM, Kittelson JM, Manco-Johnson MJ, Spyropoulos AC, Steg PG, Stence NV, Turpie AG, Schulman S; Kids-DOTT Trial Investigators. Goldenberg NA, et al. Among authors: spyropoulos ac. J Thromb Haemost. 2015 Sep;13(9):1597-605. doi: 10.1111/jth.13038. Epub 2015 Aug 11. J Thromb Haemost. 2015. PMID: 26118944 Free PMC article. Clinical Trial.
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG, Halperin J, Haskell L, Hiatt WR, Maynard GA, Peters G, Spiro T, Steg PG, Suh EY, Weitz JI. Raskob GE, et al. Among authors: spyropoulos ac. Thromb Haemost. 2016 Jun 2;115(6):1240-8. doi: 10.1160/TH15-09-0756. Epub 2016 Feb 4. Thromb Haemost. 2016. PMID: 26842902 Free article. Clinical Trial.
285 results